Egetis Therapeutics AB (publ) (STO:EGTX)
11.12
0.00 (0.00%)
Nov 20, 2026, 5:29 PM CET
Egetis Therapeutics AB Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Egetis Therapeutics AB stock has a consensus rating of "Hold" and an average price target of krĀ 11.21. The average 1-year stock price forecast is 0.81% higher than the current stock price, while the lowest is krĀ 4.30 (-61.33%) and the highest is krĀ 18.00 (+61.87%).
Price Target: krĀ 11.21 (+0.81%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Egetis Therapeutics AB stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Downgrades krĀ 33.00 → krĀ 11.25 | Hold | Downgrades | krĀ 33.00 → krĀ 11.25 | +1.17% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
537.63M
from 62.40M
Increased by 761.59%
Revenue Next Year
510.48M
from 537.63M
Decreased by -5.05%
EPS This Year
-0.76
from -0.90
EPS Next Year
-0.22
from -0.76
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.